Sign In
Buy MNMD
$20.69
+0 (+0%)
At Close: Jun 18, 2026
Short Interest in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Grows By 19.4%
04:53am, Wednesday, 21'st Jan 2026
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD - Get Free Report) saw a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 15,054,6
Mind Medicine (MindMed) Inc. (MNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
07:16pm, Wednesday, 14'th Jan 2026
Mind Medicine (MindMed) Inc. (MNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Mind Medicine (MindMed) (NASDAQ:MNMD) CEO Robert Barrow Sells 25,791 Shares of Stock
05:03am, Tuesday, 30'th Dec 2025
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD - Get Free Report) CEO Robert Barrow sold 25,791 shares of the business's stock in a transaction on Friday, December 26th. The shares were sold at an average
MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026?
10:50am, Monday, 29'th Dec 2025
MNMD has surged 101% in six months with MM120 advancing in phase III for GAD and MDD. Pivotal readouts are slated for 2026.
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Average Rating of “Buy” from Analysts
02:02am, Friday, 26'th Dec 2025
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD - Get Free Report) has received a consensus rating of "Buy" from the twelve analysts that are presently covering the stock, MarketBeat.com reports. One resea
MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference
07:01am, Thursday, 18'th Dec 2025
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to trea
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026
10:26am, Tuesday, 16'th Dec 2025
After a weak first half, the drug and biotech sector has recovered in the past 2-3 months with large drugmakers like Pfizer, AstraZeneca, Eli Lilly and Novo Nordisk signing drug pricing agreements wit
MindMed Announces New Employee Inducement Grant
04:01pm, Monday, 15'th Dec 2025
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to trea
MindMed Announces New Employee Inducement Grants
04:01pm, Monday, 01'st Dec 2025
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to trea
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Average Recommendation of “Buy” from Analysts
01:27am, Monday, 01'st Dec 2025
Shares of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD - Get Free Report) have received an average recommendation of "Buy" from the eleven research firms that are currently covering the company, Marketb
Mind Medicine (MindMed) Inc. (MNMD) Q3 2025 Earnings Call Transcript
09:46pm, Thursday, 06'th Nov 2025
Mind Medicine (MindMed) Inc. ( MNMD ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Robert Barrow - CEO & Director Daniel Karlin - Chief Medical Officer Brandi Roberts - Chie
MindMed Reports Q3 2025 Financial Results and Business Updates
04:01pm, Thursday, 06'th Nov 2025
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain
MindMed to Participate in Upcoming Investor Conferences
07:01am, Wednesday, 05'th Nov 2025
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to trea
MindMed Announces New Employee Inducement Grant
04:01pm, Monday, 03'rd Nov 2025
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to trea
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to trea
